Molsidomin-LF

General characteristics. Structure:

Active ingredient: 2 mg or 4 mg of Molsidominum.

Excipients: magnesium stearate, кросповидон, lactose monohydrate.

The drug improving quality of life of the patient due to decrease in frequency of the attacks of stenocardia arising at an exercise stress.

Indications to use:

- Prevention of attacks of stenocardia;

- Chronic heart failure (as a part of a combination therapy with cardiac glycosides, diuretics).

Route of administration and doses:

Pill should be taken in time or after food, washing down with enough liquid (1/2 glasses).

The drug Molsidomin-LF is accepted at regular intervals.

The dose of drug depends on severity of a disease, and reaction of the patient to treatment.

In an initiation of treatment about 2 mg (1 tablet Molsidominum - LF a dosage of 2 mg) - 2 times a day (4 mg of Molsidominum) are appointed.

The maintenance therapy usually makes: 4 mg (2 tablets Molsidominum - LF a dosage 2 mg or 1 tablet Molsidominum - LF a tablet a dosage of 4 mg) 2 times a day (8 mg of Molsidominum). In certain cases appoint on 2 mg (1 tablet Molsidominum - LF a dosage of 2 mg) 2-3 times a day (4 to 6 mg of Molsidominum).

In hard cases - on 4 mg (2 tablets Molsidominum - LF a dosage 2 mg or 1 tablet Molsidominum - LF a tablet a dosage of 4 mg) 3-4 times a day (12-16 mg of Molsidominum).

Elderly people with a liver or renal failure need to apply lower doses established individually.

Features of use:

Molsidominum - LF is not applicable for stopping of attacks of stenocardia!

It is necessary to approach individually a drug dosing at patients with high risk of development of arterial hypotension.

In the acute period of a myocardial infarction drug can be used only after stabilization of indicators of a hemodynamics.

At a renal failure concentration of Molsidominum in a blood plasma does not change. The drug Molsidomin-LF can be combined with other anti-anginal means (for example, to add to two - or to ternary treatment - nitrates, blockers of "slow" calcium channels and blockers of beta adrenoceptors).

At an abnormal liver function, only at the expressed its decrease (increase of bromsulfaleinovy test to 20-50%) concentration of Molsidominum in a blood plasma and an elimination half-life increases that can demand correction of a dose of drug.

During treatment it is necessary to exclude alcohol intake.

Medicine contains lactoses monohydrate, patients should not appoint it with a rare inherited disorder of tolerance to a galactose, hereditary deficit of lactase or a syndrome of disturbance of absorption of glucose galactose.

Drug is not used during pregnancy. In need of purpose of drug in the period of a lactation it is necessary to refuse breastfeeding.

During treatment (especially at the beginning) it is necessary to refrain from driving of motor transport and occupations potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions.

Side effects:

Disturbances from a nervous system: in the beginning treatments sometimes - a headache, it is rare - dizziness, increased fatigue, delay of psychomotor reactions.

Disturbances from a GIT: seldom - nausea, appetite loss, diarrhea.

Disturbances from cardiovascular: often - the expressed lowering of arterial pressure, sometimes up to a collapse, is rare - tachycardia, orthostatic hypotension, erubescence of the person.

Disturbances from immune system: seldom - allergic reactions (an itch, skin rash, a bronchospasm), with an unknown frequency - development of an acute anaphylaxis.

Disturbance from blood and lymphatic system: thrombocytopenia.

Interaction with other medicines:

At simultaneous use of Molsidomina-LF with peripheral vazodelatator, blockers of "slow" calcium channels, antihypertensives and ethanol the hypotensive effect amplifies.

The concomitant use of drug with acetylsalicylic acid increases antiagrigantny activity.

There is an increased risk of development of aretrialny hypotension at a concomitant use of inhibitors of phosphodiesterase 5 (FDE 5), such as sildenafit, tadalafit, vardenafit. Combined use of FDE 5 with Molsidominum is contraindicated.

There is an increased risk of development of arterial hypotension at a concomitant use of Molsidominum and a sapropterin.

Contraindications:

- Hypersensitivity to Molsidominum or to any of drug components;

- Acute circulatory unefficiency (shock, collapse);

- Low filling pressure of a left ventricle at an acute myocardial infarction and a left ventricular failure;

- Heavy arterial hypotension (systolic ABP less than 100 mm Hg);

- Pregnancy and period of breastfeeding;

- - sildenafit simultaneous use of inhibitors of phosphodiesterase of type 5 (FDE 5), tadalafit, vardenafit - in connection with high risk of development of arterial hypotension;

- Age up to 18 years;

- A lactose intolerance, deficit of lactase, a syndrome of glyukozo-galaktozny malabsorption (because drug contains lactoses monohydrate).

Drug is appointed with care: the patient with disturbances of cerebral circulation, with the increased intracranial pressure, with tendency to arterial hypotension, elderly patients, after the postponed myocardial infarction, the patient with glaucoma (especially closed-angle), at a hypertrophic subaortic stenosis, chronic cardial compression, a cardiac tamponade, aortal and mitral stenoses.

Overdose:

At reception of a large amount of drug the following symptoms can be observed: a severe headache, the expressed lowering of arterial pressure, tachycardia.

Treatment: it is necessary to provoke vomiting, to carry out a gastric lavage, to apply symptomatic therapy.

Storage conditions:

In the place protected from moisture and light at a temperature not above 25 °C. To store in the place, unavailable to children. Period of validity 2 years.

Issue conditions:

According to the recipe

Packaging:

On 3 or 6 blister strip packagings on 10 tablets together with the application instruction in a pack from a cardboard.